Pharmacogenetics in immunosuppressants: Impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 601-607

  Quteineh, Lina ^a,b   Verstuyft, Celine ^c,d  

^a AL QUDS UNIVERSITY   (Palestine)

^b HÔPITAL SAINT ANTOINE   (France)

^c Department of Molecular Genetics Pharmacogenetic and Hormonology   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

calcineurin inhibitors; CYP3A5; pediatric transplantation; pharmacogenetics; pharmacokinetics

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EVEROLIMUS; GLYCOPROTEIN P; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLELE; CHILD; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSPORT; EXON; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ABSORPTION; INTRON; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; NEPHROTOXICITY; PEDIATRIC SURGERY; PHARMACOGENETICS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; TREMOR; WILD TYPE;

ADOLESCENT; ADULT; BIOTRANSFORMATION; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DRUG MONITORING; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PHARMACOGENETICS; PHENOTYPE;

EID: 77957602837     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833de1d0     Document Type: Review

References (65)

1. Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 2009; 10: 961-969.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
3. Magee JC, Bucuvalas JC, Farmer D.G., et al. Pediatric transplantation. Am J Transplant 2004; 4 (SUPPL 9): 54-71.
4. Durrbach A, Francois H, Beaudreuil S., et al. Advances in immunosuppression for renal transplantation. Nat Rev Nephrol 2010; 6: 160-167.
5. Hasenbein W, Albani J, Englert C., et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transplant 2006; 10: 938-942.
6. Kari JA, Trompeter RS What is the calcineurin inhibitor of choice for pediatric renal transplantation? Pediatr Transplant 2004; 8: 437-444.
7. Chen CJ, Clark D, Ueda K., et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990; 265: 506-514.
8. Hoppu K, Koskimies O, Holmberg C., et al. Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 1991; 5: 1-4.
9. Hoppu K, Koskimies O, Holmberg C., et al. Evidence for prehepatic metabolism of oral cyclosporine in children. Br J Clin Pharmacol 1991; 32: 477-481.
10. Wallemacq PE, Furlan V, Moller A., et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharma-cokinet 1998; 23: 367-370.
11. Zhang Y, Benet LZ The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168.
12. Lemahieu W, Maes B, Verbeke K., et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383-1391.
13. Becquemont L. Clinical relevance of pharmacogenetics. Drug Metab Rev 2003; 35: 277-285.
14. Kim JS, Aviles DH, Silverstein D.M., et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 162-169.
15. Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995; 17: 596-601.
16. Kausman JY, Patel B, Marks SD Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant 2008; 12: 329-335.
17. Neu AM, Ho PL, Fine R.N., et al. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003; 7: 217-222.
18. Montini G, Ujka F, Varagnolo C., et al. The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol 2006; 21: 719-724.
19. Dunn SP. Neoral monitoring 2 h postdose and the pediatric transplant patient. Pediatr Transplant 2003; 7: 25-30.
20. Ferraresso M, Ghio L, Zacchello G., et al. Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving A quadruple immunosuppressive regimen: the value of C2 blood levels. Transplantation 2005; 79: 1164-1168.
21. Harmon WE, Sullivan EK Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation. Kidney Int Suppl 1993; 43: S50-S55.
22. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481-495.
23. Fanta S, Jonsson S, Backman J.T., et al. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007; 64: 772-784.
24. *1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499-502.
25. Quteineh L, Verstuyft C, Furlan V., et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103: 546-552.
26. Kuehl P, Zhang J, Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
27. Hustert E, Haberl M, Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
28. Macphee IA, Fredericks S, Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
29. *18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005; 353: 187-192.
30. Girnita DM, Webber SA, Ferrell R, et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 2006; 82: 1774-1780.
31. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
32. Song P, Lamba JK, Zhang L, et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 2006; 46: 373-379.
33. Wang D, Johnson AD, Papp A.C., et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.
34. Kimchi-Sarfaty C., Oh JM, Kim I.W., et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
35. Loh PT, Lou HX, Zhao Y, et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 2008; 40: 1690-1695.
36. Crettol S, Venetz JP, Fontana M, et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008; 30: 689-699.
37. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-556.
38. Anglicheau D, Thervet E, Etienne I., et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433.
39. *3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008; 64: 1069-1084.
40. Thervet E, Anglicheau D, King B., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233-1235.
41. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
42. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154.
43. *1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471-478.
44. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-726.
45. Uesugi M, Masuda S, Katsura T., et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006; 16: 119-127.
46. Westlind A, Lofberg L, Tindberg N., et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-up-stream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-205.
47. Rivory LP, Qin H, Clarke S.J., et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000; 56: 395-398.
48. von Ahsen N., Richter M, Grupp C., et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
49. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-1896.
50. Akbas SH, Bilgen T, Keser I., et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 2006; 38: 1290-1292.
51. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-1187.
52. Mourad M, Mourad G, Wallemacq P., et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977-984.
53. Kreutz R, Zurcher H, Kain S., et al. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14: 665-671.
54. Mai I, Stormer E, Goldammer M., et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003; 43: 1101-1107.
55. Allorge D, Beaune PH, Becquemont L, et al. Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects. Ann Pharm Fr 2007; 65: 371-381.
56. Fukudo M, Yano I, Masuda S., et al. Population pharmacokinetic and pharma-cogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006; 80: 331-345.
57. Ferraresso M, Tirelli A, Ghio L., et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 2007; 11: 296-300.
58. Fanta S, Niemi M, Jonsson S., et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008; 18: 77-90.
59. Zhao W, Elie V, Roussey G., et al. Population pharmacokinetics and pharma- cogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 2009; 86: 609-618.
60. Ho H, Pinto A, Hall S.D., et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294-298.
61. Watlington CO, Kramer LB, Schuetz E.G., et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927-931.
62. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution ofrenal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52-59.
63. Goto M, Masuda S, Saito H., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451-457.
64. Hawwa AF, McKiernan PJ, Shields M, et al. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009; 68: 413-421.
65. Zheng H, Webber S, Zeevi A., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477-483.